Published in J Clin Oncol on July 21, 2014
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol (2015) 1.12
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J (2015) 1.03
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Rep (2016) 0.97
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. Oncologist (2015) 0.91
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol (2014) 0.88
Role of mTOR Inhibitors in Kidney Disease. Int J Mol Sci (2016) 0.87
Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol (2015) 0.86
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. Br J Cancer (2014) 0.84
Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol (2015) 0.84
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. Br J Cancer (2016) 0.84
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol (2015) 0.83
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget (2016) 0.83
Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Ther (2015) 0.82
Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma. Transl Cancer Res (2016) 0.82
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)†. Ann Oncol (2015) 0.79
Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. Nat Rev Clin Oncol (2017) 0.79
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. Urol Clin North Am (2015) 0.78
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol (2015) 0.78
Systemic therapy in metastatic renal cell carcinoma. World J Urol (2016) 0.77
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Int J Nephrol Renovasc Dis (2016) 0.77
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer (2014) 0.76
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest (2016) 0.76
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer (2015) 0.76
Treatment-related mortality with everolimus in cancer patients. Oncologist (2014) 0.76
Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. Front Oncol (2016) 0.75
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget (2016) 0.75
Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol (2016) 0.75
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis. Oncotarget (2017) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. J Kidney Cancer VHL (2017) 0.75
Kidney cancer: mTOR or VEGFR inhibition--get the order right. Nat Rev Urol (2014) 0.75
Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma. Mol Clin Oncol (2016) 0.75
Delayed Cytoreductive Nephrectomy Following Three Years of Targeted Therapy for Metastatic Renal Cell Carcinoma. Curr Urol (2016) 0.75
Everolimus treatment in advanced solid tumors: a personal view. Future Sci OA (2015) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. Ther Adv Urol (2015) 0.75
Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Mol Clin Oncol (2017) 0.75
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
The Role of Everolimus in Renal Cell Carcinoma. J Kidney Cancer VHL (2015) 0.75
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget (2016) 0.75
Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol (2016) 0.75
[Genitourinary malignancies and rheumatoid arthritis]. Z Rheumatol (2016) 0.75
Current Management Options in Metastatic Renal Cell Cancer. Oncol Rev (2017) 0.75
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget (2017) 0.75
Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2017) 0.75
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus (2016) 0.75
Renal cell carcinoma: the search for a reliable biomarker. Transl Cancer Res (2017) 0.75